If there’s a formula for developing the kind of corporate reputation enjoyed by Silicon Valley’s elite — those companies known for taking bold risks and transforming entire industries — it would involve having a leader like Arthur Levinson.
Levinson replaced Steve Jobs in the role of Apple chairman after Jobs’ death and served as Genentech CEO and chairman for years. He also serves on the boards of the prestigious Broad Institute and Memorial Sloan Kettering Cancer Center.
All of which is to say Levinson’s latest company, Calico, has the right man at the helm. The Alphabet-backed life sciences company’s mission is to understand the biology of aging and to come up with treatments aimed at age-related diseases, including neurodegeneration and cancer.
Other than a few studies and research partnerships, though, little has been revealed since Calico opened more than five years ago with an announcement from Google cofounder Larry Page. Nonetheless, the company boasts more than 150 employees and a world-class R&D facility, and has extended its research and commercial agreement with AbbVie through 2027.
The right formula to discover the keys to human longevity? Only time will tell.